Beijing Chunlizhengda Medical Instruments Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Beijing Chunlizhengda Medical Instruments wird ein jährliches Gewinn- und Umsatzwachstum von 29.6% bzw. 22% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 30.2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 10.4% betragen.
Wichtige Informationen
29.6%
Wachstumsrate der Gewinne
30.2%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 39.9% |
| Wachstumsrate der Einnahmen | 22.0% |
| Zukünftige Eigenkapitalrendite | 10.4% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 19 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Investors Still Waiting For A Pull Back In Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858)
Sep 30
Beijing Chunlizhengda Medical Instruments Co., Ltd. (HKG:1858) Analysts Just Slashed This Year's Revenue Estimates By 13%
Sep 11Beijing Chunlizhengda Medical Instruments' (HKG:1858) Upcoming Dividend Will Be Larger Than Last Year's
Jul 01The Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Don't Inspire Confidence
May 25We Think You Can Look Beyond Beijing Chunlizhengda Medical Instruments' (HKG:1858) Lackluster Earnings
Apr 04Beijing Chunlizhengda Medical Instruments Co., Ltd.'s (HKG:1858) Shareholders Might Be Looking For Exit
Jan 06Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Paint A Concerning Picture
Dec 06Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Paint A Concerning Picture
Aug 31Here's What's Concerning About Beijing Chunlizhengda Medical Instruments' (HKG:1858) Returns On Capital
Apr 11Here's What To Make Of Beijing Chunlizhengda Medical Instruments' (HKG:1858) Decelerating Rates Of Return
Dec 05Returns On Capital At Beijing Chunlizhengda Medical Instruments (HKG:1858) Have Hit The Brakes
Apr 28I Built A List Of Growing Companies And Beijing Chunlizhengda Medical Instruments (HKG:1858) Made The Cut
Dec 30Beijing Chunlizhengda Medical Instruments (HKG:1858) Could Become A Multi-Bagger
Dec 06Is Now The Time To Put Beijing Chunlizhengda Medical Instruments (HKG:1858) On Your Watchlist?
Sep 24We Like Beijing Chunlizhengda Medical Instruments' (HKG:1858) Returns And Here's How They're Trending
Sep 06We Take A Look At Whether Beijing Chunlizhengda Medical Instruments Co., Ltd.'s (HKG:1858) CEO May Be Underpaid
Jun 15Here's Why We Think Beijing Chunlizhengda Medical Instruments (HKG:1858) Is Well Worth Watching
Jun 05Beijing Chunlizhengda Medical Instruments (HKG:1858) Could Become A Multi-Bagger
May 09Beijing Chunlizhengda Medical Instruments Co., Ltd. Just Beat EPS By 5.1%: Here's What Analysts Think Will Happen Next
Apr 01What Type Of Shareholders Make Up Beijing Chunlizhengda Medical Instruments Co., Ltd.'s (HKG:1858) Share Registry?
Feb 22Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,592 | 374 | 333 | 362 | 3 |
| 12/31/2025 | 1,344 | 314 | 242 | 259 | 3 |
| 12/31/2024 | 1,127 | 263 | 147 | 323 | 3 |
| 9/30/2024 | 925 | 158 | 450 | 481 | N/A |
| 6/30/2024 | 1,048 | 231 | 446 | 482 | N/A |
| 3/31/2024 | 1,184 | 277 | 457 | 502 | N/A |
| 12/31/2023 | 1,209 | 278 | 478 | 512 | N/A |
| 9/30/2023 | 1,234 | 279 | 129 | 131 | N/A |
| 6/30/2023 | 1,171 | 277 | 67 | 84 | N/A |
| 3/31/2023 | 1,191 | 290 | -64 | -59 | N/A |
| 12/31/2022 | 1,202 | 308 | 16 | 41 | N/A |
| 9/30/2022 | 1,150 | 328 | -43 | 30 | N/A |
| 6/30/2022 | 1,197 | 324 | -49 | 64 | N/A |
| 3/31/2022 | 1,139 | 328 | -34 | 134 | N/A |
| 12/31/2021 | 1,108 | 322 | -35 | 165 | N/A |
| 9/30/2021 | 984 | 287 | -10 | 177 | N/A |
| 6/30/2021 | 1,013 | 322 | 137 | 256 | N/A |
| 3/31/2021 | 1,007 | 318 | 227 | 303 | N/A |
| 12/31/2020 | 938 | 283 | 237 | 261 | N/A |
| 9/30/2020 | 913 | 264 | 173 | 249 | N/A |
| 6/30/2020 | 887 | 244 | 109 | 238 | N/A |
| 3/31/2020 | 826 | 216 | 69 | 191 | N/A |
| 12/31/2019 | 855 | 237 | 99 | 232 | N/A |
| 9/30/2019 | 758 | 201 | 68 | 161 | N/A |
| 6/30/2019 | 660 | 164 | 37 | 91 | N/A |
| 3/31/2019 | 579 | 135 | 47 | 100 | N/A |
| 12/31/2018 | 498 | 106 | 56 | 109 | N/A |
| 9/30/2018 | 444 | 94 | 72 | 111 | N/A |
| 6/30/2018 | 389 | 83 | N/A | 113 | N/A |
| 3/31/2018 | 345 | 76 | N/A | 102 | N/A |
| 12/31/2017 | 300 | 68 | N/A | 90 | N/A |
| 9/30/2017 | 261 | 65 | N/A | 86 | N/A |
| 6/30/2017 | 221 | 63 | N/A | 82 | N/A |
| 3/31/2017 | 215 | 63 | N/A | 73 | N/A |
| 12/31/2016 | 208 | 63 | N/A | 65 | N/A |
| 9/30/2016 | 201 | 55 | N/A | 46 | N/A |
| 6/30/2016 | 195 | 47 | N/A | 27 | N/A |
| 3/31/2016 | 186 | 43 | N/A | 13 | N/A |
| 12/31/2015 | 177 | 38 | N/A | -1 | N/A |
| 9/30/2015 | 179 | 47 | N/A | 7 | N/A |
| 6/30/2015 | 163 | 44 | N/A | -16 | N/A |
| 3/31/2015 | 149 | 41 | N/A | 4 | N/A |
| 12/31/2014 | 135 | 37 | N/A | 24 | N/A |
| 9/30/2014 | 129 | 37 | N/A | 40 | N/A |
| 12/31/2013 | 111 | 33 | N/A | 28 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1858Das prognostizierte Gewinnwachstum (29.6% pro Jahr) liegt über der Sparquote (2.3%).
Ertrag vs. Markt: 1858Die Erträge des Unternehmens (29.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (11.6% pro Jahr).
Hohe Wachstumserträge: 1858Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: 1858Die Einnahmen des Unternehmens (22% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.8% pro Jahr).
Hohe Wachstumseinnahmen: 1858Die Einnahmen des Unternehmens (22% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1858Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (10.4%).